Fennec Pharmaceuticals Inc has seen a slight dip this week despite recent positive financial news.
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$14.79, remaining unchanged on the day but down 3.46% for the week. The company recently reported strong financial results, indicating a positive trajectory for its flagship product, PEDMARK®.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$503.69M
52W high
$15.48
52W low
$7.59
1W change
-3.46%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 532.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+532.7% Upside
Current Price
C$14.79
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
51.4%
Annualized
90-Day Vol
86.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$17.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$15.70 | C$13.14 – C$18.75 |
| 60 trading days | C$16.66 | C$12.96 – C$21.41 |
| 90 trading days | C$17.68 | C$13.00 – C$24.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Despite its recent price dip, Fennec Pharmaceuticals continues to demonstrate growth in product sales and financial stability, which may appeal to long-term investors.
Fennec Pharmaceuticals Reports Record Annual Revenue of $44.6 Million
The company achieved a 50% year-over-year growth in net product sales, suggesting strong demand for its products.
Bull case
Fennec Pharmaceuticals reported record annual revenues and notable growth in product sales. This suggests a strong market position and potential for future profitability.
Bear case
The stock has declined recently, and its negative profit margins and return on equity (ROE) may raise concerns for risk-averse investors.
Recent Price Action
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$14.79 on Wednesday, with no change from the previous day. Over the past week, the stock has experienced a decline of 3.46%. However, it has shown a significant increase of 19.27% over the past month and a remarkable 42.07% year-to-date performance.
Company News and Financial Performance
Fennec Pharmaceuticals recently announced record annual revenue, with net PEDMARK® product sales reaching $44.6 million, marking a 50% increase year-over-year. The fourth quarter of 2025 also saw a significant jump in sales, up 75% compared to the previous year. The company completed an oversubscribed equity offering, raising $42 million, and reported positive topline results from a clinical study of PEDMARK® in Japan. These developments highlight Fennec's growth trajectory and commitment to expanding its market presence.
Technical Picture
In terms of technical analysis, Fennec Pharmaceuticals is currently trading above both its 50-day moving average of C$12.82 and its 200-day moving average of C$11.29, indicating a bullish trend in the medium to long term. The stock has a beta of 1.07, suggesting it is slightly more volatile than the broader market. The 52-week range for FRX.TO is C$7.59 to C$15.48, with the current price sitting at approximately 91% of this range. However, the recent trading volume of 286 shares is significantly lower than the 20-day average volume of 1,531 shares, indicating reduced investor interest in the short term.
Advertisement
